SI3243826T1 - Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov - Google Patents
Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitovInfo
- Publication number
- SI3243826T1 SI3243826T1 SI201331625T SI201331625T SI3243826T1 SI 3243826 T1 SI3243826 T1 SI 3243826T1 SI 201331625 T SI201331625 T SI 201331625T SI 201331625 T SI201331625 T SI 201331625T SI 3243826 T1 SI3243826 T1 SI 3243826T1
- Authority
- SI
- Slovenia
- Prior art keywords
- imidazothiadiazole
- par4
- inhibitors
- platelet aggregation
- activated receptor
- Prior art date
Links
- BOXRDDIXJOUZLV-UHFFFAOYSA-N 2h-imidazo[4,5-d]thiadiazole Chemical compound N1SC2=NC=NC2=N1 BOXRDDIXJOUZLV-UHFFFAOYSA-N 0.000 title 1
- 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 title 1
- 101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 title 1
- 102000004885 Protease-activated receptor 4 Human genes 0.000 title 1
- 108090001010 Protease-activated receptor 4 Proteins 0.000 title 1
- 150000005235 imidazopyrazines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261638577P | 2012-04-26 | 2012-04-26 | |
US201361787680P | 2013-03-15 | 2013-03-15 | |
EP17172927.0A EP3243826B1 (en) | 2012-04-26 | 2013-04-24 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3243826T1 true SI3243826T1 (sl) | 2020-03-31 |
Family
ID=48407806
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201331625T SI3243826T1 (sl) | 2012-04-26 | 2013-04-24 | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
SI201332026T SI3632919T1 (sl) | 2012-04-26 | 2013-04-24 | Farmacevtski sestavki vsebujoč derivate imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
SI201330734T SI2841437T1 (sl) | 2012-04-26 | 2013-04-24 | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201332026T SI3632919T1 (sl) | 2012-04-26 | 2013-04-24 | Farmacevtski sestavki vsebujoč derivate imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
SI201330734T SI2841437T1 (sl) | 2012-04-26 | 2013-04-24 | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
Country Status (36)
Country | Link |
---|---|
US (5) | US9688695B2 (zh) |
EP (3) | EP3632919B1 (zh) |
JP (1) | JP6073464B2 (zh) |
KR (3) | KR102176379B1 (zh) |
CN (2) | CN108383858A (zh) |
AR (1) | AR090834A1 (zh) |
AU (1) | AU2013251632B2 (zh) |
BR (1) | BR112014026643B1 (zh) |
CA (1) | CA2871650C (zh) |
CL (1) | CL2014002915A1 (zh) |
CO (1) | CO7160040A2 (zh) |
CY (2) | CY1119466T1 (zh) |
DK (3) | DK3632919T3 (zh) |
EA (1) | EA026724B1 (zh) |
ES (3) | ES2935173T3 (zh) |
FI (1) | FI3632919T3 (zh) |
HK (1) | HK1203953A1 (zh) |
HR (3) | HRP20221495T1 (zh) |
HU (3) | HUE048654T2 (zh) |
IL (1) | IL235246B (zh) |
LT (2) | LT3632919T (zh) |
MX (1) | MX354175B (zh) |
MY (1) | MY175061A (zh) |
NZ (1) | NZ631027A (zh) |
PE (1) | PE20142285A1 (zh) |
PH (1) | PH12014502173B1 (zh) |
PL (3) | PL2841437T3 (zh) |
PT (3) | PT3243826T (zh) |
RS (3) | RS56395B1 (zh) |
SG (1) | SG11201406757SA (zh) |
SI (3) | SI3243826T1 (zh) |
TN (1) | TN2014000436A1 (zh) |
TW (1) | TWI572605B (zh) |
UY (1) | UY34763A (zh) |
WO (1) | WO2013163279A1 (zh) |
ZA (1) | ZA201407799B (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150003766A (ko) | 2012-04-26 | 2015-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체 |
BR112014026493A2 (pt) * | 2012-04-26 | 2017-06-27 | Bristol Myers Squibb Co | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta |
KR102176379B1 (ko) * | 2012-04-26 | 2020-11-09 | 브리스톨-마이어스 스큅 컴퍼니 | 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체 |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
ES2790419T3 (es) | 2013-01-15 | 2020-10-27 | Incyte Holdings Corp | Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM |
US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
US9617279B1 (en) | 2014-06-24 | 2017-04-11 | Bristol-Myers Squibb Company | Imidazooxadiazole compounds |
US9598419B1 (en) | 2014-06-24 | 2017-03-21 | Universite De Montreal | Imidazotriazine and imidazodiazine compounds |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016134450A1 (en) | 2015-02-26 | 2016-09-01 | Université de Montréal | Imidazopyridazine and imidazothiadiazole compounds |
EP3262052A1 (en) | 2015-02-26 | 2018-01-03 | Bristol-Myers Squibb Company | Benzothiazole and benzothiophne compounds |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
US9789087B2 (en) | 2015-08-03 | 2017-10-17 | Thomas Jefferson University | PAR4 inhibitor therapy for patients with PAR4 polymorphism |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
EP3371196B1 (en) | 2015-10-19 | 2021-10-27 | Université de Montréal | Heterocyclic compounds as inhibitors of platelet aggregation |
US9963466B2 (en) | 2016-03-07 | 2018-05-08 | Vanderbilt University | Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists |
US20190119300A1 (en) * | 2016-04-18 | 2019-04-25 | Vanderbilt University | Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists |
KR102492715B1 (ko) | 2016-07-14 | 2023-01-26 | 브리스톨-마이어스 스큅 컴퍼니 | 모노시클릭 헤테로아릴 치환된 화합물 |
KR102460385B1 (ko) | 2016-07-14 | 2022-10-27 | 브리스톨-마이어스 스큅 컴퍼니 | 비시클릭 헤테로아릴 치환된 화합물 |
EP3484894B1 (en) | 2016-07-14 | 2020-08-19 | Bristol-Myers Squibb Company | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors |
ES2800313T3 (es) | 2016-07-14 | 2020-12-29 | Bristol Myers Squibb Co | Compuestos de heteroarilo bicíclico sustituidos |
CN113480530A (zh) | 2016-12-26 | 2021-10-08 | 阿里根公司 | 芳香烃受体调节剂 |
CN111587249A (zh) | 2017-11-20 | 2020-08-25 | 阿里根公司 | 吲哚化合物及其用途 |
TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
WO2019149205A1 (zh) * | 2018-01-31 | 2019-08-08 | 江苏恒瑞医药股份有限公司 | 苯并杂芳基类衍生物、其制备方法及其在医药上的应用 |
CN110218218B (zh) * | 2018-03-01 | 2022-04-08 | 江苏恒瑞医药股份有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
CN110272436A (zh) * | 2018-03-14 | 2019-09-24 | 中国药科大学 | 氘代的咪唑并噻二唑衍生物及其医药用途 |
CN112074522B (zh) * | 2018-05-16 | 2022-08-26 | 深圳信立泰药业股份有限公司 | 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物 |
WO2019218956A1 (zh) * | 2018-05-16 | 2019-11-21 | 深圳信立泰药业股份有限公司 | 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物 |
CN110627817B (zh) * | 2018-06-25 | 2022-03-29 | 中国药科大学 | 咪唑并环类par4拮抗剂及其医药用途 |
WO2020045638A1 (ja) * | 2018-08-30 | 2020-03-05 | 日本メジフィジックス株式会社 | 放射性イミダゾチアジアゾール誘導体化合物 |
WO2020106695A1 (en) | 2018-11-19 | 2020-05-28 | Ariagen, Inc. | Methods of treating cancer |
CN113227102A (zh) * | 2018-12-21 | 2021-08-06 | 百时美施贵宝公司 | Par4抑制剂的结晶形式 |
CN111349105B (zh) * | 2018-12-24 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
CN111362970A (zh) * | 2018-12-25 | 2020-07-03 | 天津药物研究院有限公司 | 苯并呋喃类衍生物及其制备方法和用途 |
KR20210151951A (ko) | 2019-04-15 | 2021-12-14 | 아리아젠, 인크. | 키랄 인돌 화합물 및 그 용도 |
EP3782702A1 (en) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compounds and use thereof for the treatment of infectious diseases and cancer |
CN112079791A (zh) * | 2020-08-21 | 2020-12-15 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用 |
CN113150005B (zh) * | 2021-04-09 | 2022-08-30 | 中国药科大学 | 喹喔啉类化合物、制备方法及其在医药上的应用 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2823686A1 (de) * | 1978-05-31 | 1979-12-06 | Bayer Ag | Imidazo eckige klammer auf 2.1-b eckige klammer zu eckige klammer auf 1.3.4 eckige klammer zu -thiadiazole |
US4444770A (en) | 1980-05-29 | 1984-04-24 | Bayer Aktiengesellschaft | New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use |
DE3020421A1 (de) | 1980-05-29 | 1981-12-10 | Bayer Ag, 5090 Leverkusen | Imidazoazolalkensaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln |
DE3446778A1 (de) * | 1984-12-21 | 1986-07-03 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
US4925849A (en) | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
EP0497258B1 (en) | 1991-01-29 | 2002-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer |
US5342851A (en) * | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途 |
JP4345230B2 (ja) | 1998-03-10 | 2009-10-14 | 小野薬品工業株式会社 | カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤 |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
WO2001027118A2 (de) | 1999-10-08 | 2001-04-19 | Grünenthal GmbH | Bicyclische imidazo-5-yl-aminderivate |
DE10019714A1 (de) | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen |
US6387942B2 (en) | 2000-06-19 | 2002-05-14 | Yung Shin Pharmaceutical Ind. Co. Ltd | Method of treating disorders related to protease-activated receptors-induced cell activation |
US6673815B2 (en) | 2001-11-06 | 2004-01-06 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
CA2364985A1 (en) | 2001-12-14 | 2003-06-14 | John W. Gillard | Imidazo(2,1-b)thiadiazole sulfonamides |
KR101064077B1 (ko) | 2003-01-10 | 2011-09-08 | 이데미쓰 고산 가부시키가이샤 | 질소-함유 헤테로환 유도체 및 이를 이용한 유기 전기발광소자 |
CA2527906A1 (en) | 2003-06-13 | 2004-12-23 | Aegera Therapeutics, Inc. | Acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides and uses thereof |
WO2004111060A1 (en) | 2003-06-13 | 2004-12-23 | Aegera Therapeutics Inc. | IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES |
ATE362367T1 (de) | 2003-10-31 | 2007-06-15 | Janssen Pharmaceutica Nv | Phenoxyessigsäure-derivate als peroxisom- proliferator-aktivierte rezeptor (ppar) dual- agonisten |
CA2545711A1 (en) | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
CA2555263A1 (en) | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
WO2006109846A1 (ja) * | 2005-04-06 | 2006-10-19 | Takeda Pharmaceutical Company Limited | トリアゾール誘導体およびその用途 |
AU2006261917A1 (en) | 2005-06-24 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Radiolabeled-pegylation of ligands for use as imaging agents |
JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
MX2008011615A (es) | 2006-03-14 | 2008-09-22 | Amgen Inc | Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos. |
KR20090033833A (ko) | 2006-04-13 | 2009-04-06 | 에게라 쎄라퓨틱스 인코포레이티드 | 신경병증성 통증의 치료를 위한 이미다조[2,1―b]―1,3,4―티아디아졸―2―술폰아미드 화합물의 이용 |
DE102006054757A1 (de) | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
EP2155747B1 (en) | 2007-05-10 | 2012-10-24 | GE Healthcare Limited | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
US20090176778A1 (en) | 2007-08-10 | 2009-07-09 | Franz Ulrich Schmitz | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
WO2009027733A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents |
GB0718735D0 (en) | 2007-09-25 | 2007-11-07 | Prolysis Ltd | Antibacterial agents |
JP2011506487A (ja) | 2007-12-21 | 2011-03-03 | ザ・ユニバーシティ・オブ・シドニー | トランスロケータータンパク質リガンド |
BRPI0909469A2 (pt) | 2008-03-31 | 2015-12-29 | Metabolex Inc | compostos de oximetileno de arila e usos dos mesmos |
CN102159582B (zh) * | 2008-07-15 | 2014-05-07 | 赛诺菲-安万特 | 作为Edg-1受体激动剂的噁唑并嘧啶 |
DK2331530T3 (da) | 2008-09-26 | 2013-11-11 | Nat Health Research Institutes | Kondenserede multicycliske forbindelser som proteinkinaseinhibitorer |
JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
BR112012014858A2 (pt) * | 2009-12-18 | 2016-03-29 | Mitsubishi Tanabe Pharma Corp | agente antiplaqueta |
CN102372701A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 氮杂双环己烷类衍生物、其制备方法及其在医药上的应用 |
CN103153300A (zh) | 2010-08-11 | 2013-06-12 | 米伦纽姆医药公司 | 杂芳基化合物和其用途 |
CN103874496A (zh) | 2011-08-22 | 2014-06-18 | 默沙东公司 | 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途 |
KR102176379B1 (ko) * | 2012-04-26 | 2020-11-09 | 브리스톨-마이어스 스큅 컴퍼니 | 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체 |
MX2014012803A (es) * | 2012-04-26 | 2015-01-15 | Squibb Bristol Myers Co | Peptidos agonistas de receptor activado por proteasa tipo 4 (par4). |
BR112014026493A2 (pt) | 2012-04-26 | 2017-06-27 | Bristol Myers Squibb Co | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta |
KR20150003766A (ko) | 2012-04-26 | 2015-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체 |
PE20160802A1 (es) | 2012-04-27 | 2016-09-03 | Novartis Ag | Inhibidores de dgat1 de eter ciclico de cabeza de puente |
NZ701626A (en) | 2012-05-15 | 2016-02-26 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
MY185217A (en) | 2012-06-21 | 2021-04-30 | Hoffmann La Roche | Analogs of glucagon exhibiting gip receptor activity |
AR092348A1 (es) | 2012-07-11 | 2015-04-15 | Hoffmann La Roche | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc |
TW201414737A (zh) | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
EP2875029B8 (en) | 2012-07-18 | 2021-12-15 | University of Notre Dame du Lac | 5,5-heteroaromatic anti-infective compounds |
TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
MY172021A (en) | 2012-10-16 | 2019-11-12 | Janssen Sciences Ireland Uc | Rsv antiviral compounds |
SG11201504633PA (en) | 2012-12-19 | 2015-07-30 | Novartis Ag | Autotaxin inhibitors |
CA2893843C (en) | 2012-12-21 | 2018-09-04 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
-
2013
- 2013-04-24 KR KR1020207009636A patent/KR102176379B1/ko active IP Right Grant
- 2013-04-24 LT LTEP19192142.8T patent/LT3632919T/lt unknown
- 2013-04-24 UY UY0001034763A patent/UY34763A/es unknown
- 2013-04-24 MX MX2014012296A patent/MX354175B/es active IP Right Grant
- 2013-04-24 SI SI201331625T patent/SI3243826T1/sl unknown
- 2013-04-24 US US14/396,771 patent/US9688695B2/en active Active
- 2013-04-24 PE PE2014001782A patent/PE20142285A1/es active IP Right Grant
- 2013-04-24 SI SI201332026T patent/SI3632919T1/sl unknown
- 2013-04-24 PT PT171729270T patent/PT3243826T/pt unknown
- 2013-04-24 HU HUE17172927A patent/HUE048654T2/hu unknown
- 2013-04-24 RS RS20170983A patent/RS56395B1/sr unknown
- 2013-04-24 HU HUE19192142A patent/HUE060743T2/hu unknown
- 2013-04-24 SI SI201330734T patent/SI2841437T1/sl unknown
- 2013-04-24 DK DK19192142.8T patent/DK3632919T3/da active
- 2013-04-24 PL PL13721857T patent/PL2841437T3/pl unknown
- 2013-04-24 BR BR112014026643-3A patent/BR112014026643B1/pt active IP Right Grant
- 2013-04-24 HR HRP20221495TT patent/HRP20221495T1/hr unknown
- 2013-04-24 AU AU2013251632A patent/AU2013251632B2/en active Active
- 2013-04-24 ES ES19192142T patent/ES2935173T3/es active Active
- 2013-04-24 PL PL17172927T patent/PL3243826T3/pl unknown
- 2013-04-24 CN CN201810251394.6A patent/CN108383858A/zh active Pending
- 2013-04-24 HU HUE13721857A patent/HUE034566T2/hu unknown
- 2013-04-24 ES ES17172927T patent/ES2770026T3/es active Active
- 2013-04-24 PT PT137218574T patent/PT2841437T/pt unknown
- 2013-04-24 WO PCT/US2013/037956 patent/WO2013163279A1/en active Application Filing
- 2013-04-24 KR KR1020147030174A patent/KR102098804B1/ko active IP Right Grant
- 2013-04-24 DK DK13721857.4T patent/DK2841437T3/en active
- 2013-04-24 AR ARP130101380A patent/AR090834A1/es active IP Right Grant
- 2013-04-24 TW TW102114695A patent/TWI572605B/zh active
- 2013-04-24 LT LTEP13721857.4T patent/LT2841437T/lt unknown
- 2013-04-24 NZ NZ631027A patent/NZ631027A/en unknown
- 2013-04-24 CA CA2871650A patent/CA2871650C/en active Active
- 2013-04-24 DK DK17172927.0T patent/DK3243826T3/da active
- 2013-04-24 PL PL19192142.8T patent/PL3632919T3/pl unknown
- 2013-04-24 CN CN201380032304.XA patent/CN104583218B/zh active Active
- 2013-04-24 KR KR1020207031590A patent/KR20200127273A/ko not_active Application Discontinuation
- 2013-04-24 EA EA201491968A patent/EA026724B1/ru not_active IP Right Cessation
- 2013-04-24 FI FIEP19192142.8T patent/FI3632919T3/fi active
- 2013-04-24 ES ES13721857.4T patent/ES2640916T3/es active Active
- 2013-04-24 EP EP19192142.8A patent/EP3632919B1/en active Active
- 2013-04-24 MY MYPI2014703169A patent/MY175061A/en unknown
- 2013-04-24 EP EP13721857.4A patent/EP2841437B1/en active Active
- 2013-04-24 RS RS20191664A patent/RS59882B1/sr unknown
- 2013-04-24 EP EP17172927.0A patent/EP3243826B1/en active Active
- 2013-04-24 RS RS20230041A patent/RS63975B1/sr unknown
- 2013-04-24 SG SG11201406757SA patent/SG11201406757SA/en unknown
- 2013-04-24 JP JP2015509103A patent/JP6073464B2/ja active Active
- 2013-04-24 PT PT191921428T patent/PT3632919T/pt unknown
-
2014
- 2014-09-29 PH PH12014502173A patent/PH12014502173B1/en unknown
- 2014-10-20 TN TN2014000436A patent/TN2014000436A1/fr unknown
- 2014-10-21 IL IL235246A patent/IL235246B/en active IP Right Grant
- 2014-10-21 CO CO14232423A patent/CO7160040A2/es unknown
- 2014-10-24 ZA ZA2014/07799A patent/ZA201407799B/en unknown
- 2014-10-27 CL CL2014002915A patent/CL2014002915A1/es unknown
-
2015
- 2015-05-14 HK HK15104576.7A patent/HK1203953A1/zh unknown
-
2017
- 2017-05-12 US US15/593,534 patent/US10047103B2/en active Active
- 2017-09-28 HR HRP20171453TT patent/HRP20171453T1/hr unknown
- 2017-09-29 CY CY20171101023T patent/CY1119466T1/el unknown
-
2018
- 2018-06-27 US US16/020,043 patent/US10428077B2/en active Active
-
2019
- 2019-08-13 US US16/538,917 patent/US10822343B2/en active Active
- 2019-12-30 HR HRP20192336TT patent/HRP20192336T1/hr unknown
-
2020
- 2020-01-24 CY CY20201100069T patent/CY1122625T1/el unknown
-
2022
- 2022-09-02 US US17/902,618 patent/US20230242535A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203953A1 (zh) | 作為蛋白酶活化受體 抑制劑用於治療血小板聚集的咪唑並噻二唑和咪唑並吡嗪的衍生物 | |
IL235141A0 (en) | Imidazothiadiazole and imidazopyridazine derivatives as protease-activated receptor 4 (par4) inhibitors for the treatment of platelet aggregation | |
IL235140A0 (en) | Imidazothiadiazole derivatives as protease-activated receptor 4 (par4) inhibitors for the treatment of platelet aggregation | |
IL267066B (en) | Activin-actrii antagonists and their use for the treatment of bone and other disorders | |
SI2920149T1 (sl) | Spojine 3-aminocikloalkila kot zaviralci receptorja ROR-gama-t in uporaba teh spojin | |
EP2833889A4 (en) | PROTEIN KINASE C HEMMER AND USES THEREOF | |
PL2812374T3 (pl) | Układy spoiwa cold-box i mieszaniny do zastosowania jako dodatki do takich układów spoiwa | |
EP2800738A4 (en) | Heterocyclic compounds and methods for their use | |
IL237321A0 (en) | ddr2 inhibitors and pharmaceutical preparations containing them | |
EP2907593A4 (en) | METHOD FOR TREATING A USED VOIDABLE ARTICLE | |
EP2807153A4 (en) | Heterocyclic compounds and methods for their use | |
EP2872143A4 (en) | DI- AND TRI-HETEROARYL DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION | |
HK1206350A1 (zh) | -咪唑- -胺化合物及其作為 抑制劑的用途 | |
HK1249519A1 (zh) | Hsp90c端抑制劑及其醫藥組合物和用途 | |
HK1246694A1 (zh) | α胸腺肽用於膿毒症治療的用途 | |
PL2830980T3 (pl) | Urządzenie do wytwarzania opakowań zbiorczych |